Natural killer cells have an activated profile in early Parkinson's disease

[1]  R. Barker,et al.  B lymphocyte responses in Parkinson’s disease and their possible significance in disease progression , 2023, Brain communications.

[2]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[3]  A. Sette,et al.  Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease , 2022, Journal of Parkinson's disease.

[4]  C. Marras,et al.  Epidemiological Evidence for an Immune Component of Parkinson’s Disease , 2022, Journal of Parkinson's disease.

[5]  Kelly B. Menees,et al.  New Insights and Implications of Natural Killer Cells in Parkinson’s Disease , 2022, Journal of Parkinson's disease.

[6]  C. Comi,et al.  T Lymphocytes in Parkinson’s Disease , 2022, Journal of Parkinson's disease.

[7]  J. Pu,et al.  Specific immune status in Parkinson’s disease at different ages of onset , 2022, NPJ Parkinson's disease.

[8]  C. Schulte,et al.  Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson’s disease and cognition , 2022, Brain, Behavior, and Immunity.

[9]  C. Williams-Gray,et al.  T lymphocyte senescence is attenuated in Parkinson’s disease , 2021, Journal of neuroinflammation.

[10]  Yuhu Zhang,et al.  Significant Difference of Immune Cell Fractions and Their Correlations With Differential Expression Genes in Parkinson’s Disease , 2021, Frontiers in Aging Neuroscience.

[11]  E. Tolosa,et al.  Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder , 2021, Proceedings of the National Academy of Sciences.

[12]  Jae-Kyung Lee,et al.  The role of natural killer cells in Parkinson’s disease , 2020, Experimental & Molecular Medicine.

[13]  W. Glac,et al.  Subthalamic Deep Brain Stimulation Affects Plasma Corticosterone Concentration and Peripheral Immunity Changes in Rat Model of Parkinson’s Disease , 2020, Journal of Neuroimmune Pharmacology.

[14]  S. Mallal,et al.  α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease , 2020, Nature Communications.

[15]  R. Barker,et al.  Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease , 2020, Brain, Behavior, and Immunity.

[16]  C. Gutekunst,et al.  NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy , 2020, Proceedings of the National Academy of Sciences.

[17]  Benedict Michael,et al.  Faculty Opinions recommendation of Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[18]  F. Blandini,et al.  Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us? , 2019, Front. Neurol..

[19]  M. Clatworthy,et al.  A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease , 2018, Front. Neurol..

[20]  Chao Yang,et al.  Natural Killer Cells: Development, Maturation, and Clinical Utilization , 2018, Front. Immunol..

[21]  J. Madrigal,et al.  Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma , 2018, Front. Immunol..

[22]  B. Racette,et al.  Immunosuppressants and risk of Parkinson disease , 2018, Annals of clinical and translational neurology.

[23]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[24]  Yousheng Xiao,et al.  Peripheral Lymphocyte Subsets as a Marker of Parkinson’s Disease in a Chinese Population , 2017, Neuroscience Bulletin.

[25]  S. Klein,et al.  Sex differences in immune responses , 2016, Nature Reviews Immunology.

[26]  T. Beach,et al.  Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease , 2015, BMC Medical Genomics.

[27]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[28]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[29]  G. Halliday,et al.  Reduced T helper and B lymphocytes in Parkinson's disease , 2012, Journal of Neuroimmunology.

[30]  N. Kuriyama,et al.  Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease , 2012, Geriatrics & gerontology international.

[31]  D. Dickson,et al.  Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress‐induced neuronal death , 2011, Human mutation.

[32]  M. Gerbin,et al.  What is the functional significance of nondominant arm tremor in essential tremor? , 2010, Movement disorders : official journal of the Movement Disorder Society.

[33]  L. Schöls,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[34]  A. Goris,et al.  Association of the human leucocyte antigen region with susceptibility to Parkinson's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[36]  M. Nakashima,et al.  Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. , 2008, Parkinsonism & related disorders.